Novel Therapies in Paediatric NHL

Amos Burke; Joerg Krueger; Birte Wistinghausen

doi:10.1007/978-3-030-11769-6_26

Novel Therapies in Paediatric NHL

Amos Burke, Joerg Krueger, Birte Wistinghausen^*

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Even though current treatment for paediatric NHL results in excellent outcomes for most children, the burden of therapy and associated morbidities are still significant. In addition, patients with relapsed or refractory disease still have a dismal prognosis with less than 30% of patients achieving a long-term cure. Further intensification of chemotherapy is unlikely to increase cure rates. Novel and targeted therapies that are effective in curing relapsed patients and potentially reduce toxicities in newly diagnosed patients whilst preserving their excellent outcomes are needed. Numerous novel agents approved or in clinical trials for adult NHL are of potential interest for paediatric NHL and will be discussed in this chapter. In addition, the current status of immunotherapy with a focus on chimeric antigen receptor (CAR) and tumour-associated antigen (TAA) T-cells will be reviewed.

Original language	English
Title of host publication	Non-Hodgkin’s Lymphoma in Childhood and Adolescence
Publisher	Springer
Pages	315-335
Number of pages	21
ISBN (Electronic)	9783030117696
ISBN (Print)	9783030117689
DOIs	https://doi.org/10.1007/978-3-030-11769-6_26
Publication status	Published - 1 Jan 2019

Bibliographical note

Publisher Copyright:
© Springer Nature Switzerland AG 2019.

Keywords

Cellular therapy
Immunotherapy
Nhl
Novel therapy
Small-molecule inhibitors
Targeted therapy

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-11769-6_26

Cite this

@inbook{558c8efaf12a49a9a021a9f0a8e27b30,

title = "Novel Therapies in Paediatric NHL",

abstract = "Even though current treatment for paediatric NHL results in excellent outcomes for most children, the burden of therapy and associated morbidities are still significant. In addition, patients with relapsed or refractory disease still have a dismal prognosis with less than 30% of patients achieving a long-term cure. Further intensification of chemotherapy is unlikely to increase cure rates. Novel and targeted therapies that are effective in curing relapsed patients and potentially reduce toxicities in newly diagnosed patients whilst preserving their excellent outcomes are needed. Numerous novel agents approved or in clinical trials for adult NHL are of potential interest for paediatric NHL and will be discussed in this chapter. In addition, the current status of immunotherapy with a focus on chimeric antigen receptor (CAR) and tumour-associated antigen (TAA) T-cells will be reviewed.",

keywords = "Cellular therapy, Immunotherapy, Nhl, Novel therapy, Small-molecule inhibitors, Targeted therapy",

author = "Amos Burke and Joerg Krueger and Birte Wistinghausen",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2019.",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/978-3-030-11769-6_26",

language = "English",

isbn = "9783030117689",

pages = "315--335",

booktitle = "Non-Hodgkin{\textquoteright}s Lymphoma in Childhood and Adolescence",

publisher = "Springer",

}

TY - CHAP

T1 - Novel Therapies in Paediatric NHL

AU - Burke, Amos

AU - Krueger, Joerg

AU - Wistinghausen, Birte

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2019.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Even though current treatment for paediatric NHL results in excellent outcomes for most children, the burden of therapy and associated morbidities are still significant. In addition, patients with relapsed or refractory disease still have a dismal prognosis with less than 30% of patients achieving a long-term cure. Further intensification of chemotherapy is unlikely to increase cure rates. Novel and targeted therapies that are effective in curing relapsed patients and potentially reduce toxicities in newly diagnosed patients whilst preserving their excellent outcomes are needed. Numerous novel agents approved or in clinical trials for adult NHL are of potential interest for paediatric NHL and will be discussed in this chapter. In addition, the current status of immunotherapy with a focus on chimeric antigen receptor (CAR) and tumour-associated antigen (TAA) T-cells will be reviewed.

AB - Even though current treatment for paediatric NHL results in excellent outcomes for most children, the burden of therapy and associated morbidities are still significant. In addition, patients with relapsed or refractory disease still have a dismal prognosis with less than 30% of patients achieving a long-term cure. Further intensification of chemotherapy is unlikely to increase cure rates. Novel and targeted therapies that are effective in curing relapsed patients and potentially reduce toxicities in newly diagnosed patients whilst preserving their excellent outcomes are needed. Numerous novel agents approved or in clinical trials for adult NHL are of potential interest for paediatric NHL and will be discussed in this chapter. In addition, the current status of immunotherapy with a focus on chimeric antigen receptor (CAR) and tumour-associated antigen (TAA) T-cells will be reviewed.

KW - Cellular therapy

KW - Immunotherapy

KW - Nhl

KW - Novel therapy

KW - Small-molecule inhibitors

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85133993258&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-11769-6_26

DO - 10.1007/978-3-030-11769-6_26

M3 - Chapter

AN - SCOPUS:85133993258

SN - 9783030117689

SP - 315

EP - 335

BT - Non-Hodgkin’s Lymphoma in Childhood and Adolescence

PB - Springer

ER -

Novel Therapies in Paediatric NHL

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this